VivoSeq
Other

Diagnosis

0

Pipeline Programs↗

6

Active Trials↗

2

Companies Involved↗

Diagnosis is an early-stage landscape with 0 programs across 2 companies. The most active players are Sinotau Pharmaceutical Group, Takeda.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

87/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Sinotau Pharmaceutical Group

0 programs

PreclinicalTakeda logo

Takeda

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

32

clinical trials

Completed13 · 41%
Unknown status11 · 34%
Recruiting5 · 16%
Withdrawn2 · 6%
Active, not recruiting1 · 3%

Clinical Trials

Trial Activity

32 trials

Study of the Value of hPG80 (Circulating Progastrin) for the Diagnosis of Neuroendocrine Tumours in Patients With an MEN1 Mutation
Recruiting·—·N/A·NCT06430021·297 enrolled
Evaluation of a New Multiplex Quantitative PCR Technique for the Diagnosis of Echinococcosis
Recruiting·—·N/A·NCT05824442·43 enrolled
A Dual-targeting Tracer TATE-RGD for the Diagnosis of SSTR- and RGD- Positive Tumors
Recruiting·PPeking Union Medical College Hospital·Phase 1·NCT06632860·40 enrolled
Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders
Recruiting·AAssistance Publique - Hôpitaux de Paris·N/A·NCT06147414·550 enrolled
The Effect of Blended Learning Approach on Psychosocial Nursing Diagnoses in Nursing Students: A Randomized Controlled Study
Recruiting·UUniversity of Yalova·Preclinical·NCT07670351·52 enrolled
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
Active, not recruiting·AAbramson Cancer Center at Penn Medicine·N/A·NCT01985919·206 enrolled
Evaluation of XTR004 as a Novel 18F-labeled PET MPI Tracer in Diagnosis of Known or Suspected CAD
Completed·SSinotau Pharmaceutical Group·Phase 2·NCT05885841·83 enrolled
Marker for FAI Diagnosis
Completed·—·N/A·NCT02880085·20 enrolled
Medico-economic Evaluation of Different High-throughput Sequencing Strategies in the Diagnosis of Patients With Intellectual Deficiency
Completed·—·N/A·NCT03287206·337 enrolled
Impact of FBB PET Amyloid Imaging in Change of Diagnosis in Patients With AD
Completed·PPiramal Imaging Limited·Phase 4·NCT02681172·218 enrolled
Analysis of the Modulation of Serum Hepcidin Level in Response to Iron Oral Intake: Potential Interest for the Differential Diagnosis Between Ferroportin Disease and Dysmetabolic Hepatosiderosis.
Completed·RRennes University Hospital·Phase 2·NCT01949467·62 enrolled
Proof of Concept Study Concerning Efficacy of P03277 MR Imaging in HCC Diagnosis
Completed·GGuerbet·Phase 2·NCT02973516·41 enrolled
ANDDI-PRENATOME - Feasibility Study for a " Fast " Pangenomic High Throughput Sequencing Analysis in Prenatal Diagnosis
Completed·—·N/A·NCT03964441·149 enrolled
Preimplantation Genetic Diagnosis (PGD) With Gonadotropin-releasing Hormone (GnRH) Agonist Versus Antagonist
Completed·UUniversitair Ziekenhuis Brussel·Phase 4·NCT01888744·120 enrolled
A Test and Treat Strategy in New HIV Diagnosis.
Completed·—·Phase 3·NCT04416906·100 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)